久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

捷克 SOTIO, 舒迪安,  
舒迪安舒迪安是一家生物技術(shù)公司，致力于開發(fā)基于活化樹突狀細(xì)胞的新治療方法，主要專注癌癥和自體免疫性疾病的治療。我們的使命是采用基于我們自有知識(shí)產(chǎn)權(quán)的細(xì)胞技術(shù)來開發(fā)新的治療方法，并通過我們自有的免疫療法平臺(tái)應(yīng)對(duì)很大程度上未得到滿足的醫(yī)療需求。

一大批世界知名科學(xué)家聚集在舒迪安公司位于布拉格的研究中心，，他們借助于目前最尖端的實(shí)驗(yàn)設(shè)備積極探索樹突狀細(xì)胞在免疫反應(yīng)活化治療中的應(yīng)用。

舒迪安公司通過下列方式開發(fā)最新治療方法：
采用自體細(xì)胞免疫療法治療癌癥和自體免疫疾病
采用免疫療法連同化療等其他標(biāo)準(zhǔn)治療方式提高臨床療效
研究免疫療法的長(zhǎng)期治療效果以增強(qiáng)免疫系統(tǒng)對(duì)特定疾病的反應(yīng)能力
使用廣譜的腫瘤抗原，通過患者自身樹突狀細(xì)胞的活化，來刺激復(fù)雜的免疫反應(yīng)
我公司的臨床開發(fā)方案旨在采用活化樹突狀細(xì)胞免疫療法，為某些特定的、現(xiàn)有治療手段匱乏的部分疾病拓展治療選擇。

先期通過我公司的免疫療法平臺(tái)實(shí)施的針對(duì)前列腺癌晚期病人的臨床試驗(yàn)，顯示出了令人鼓舞的實(shí)驗(yàn)效果。我們計(jì)劃2012年在全球范圍內(nèi)開展三期驗(yàn)證性臨床研究，旨在為可選治療方案有限的患者提供此種療法。

舒迪安公司建立了設(shè)施最先進(jìn)并且是歐洲最大規(guī)模之一的研發(fā)和細(xì)胞產(chǎn)品制備中心，符合最新的優(yōu)質(zhì)生產(chǎn)標(biāo)準(zhǔn)（GMP），所生產(chǎn)的基于細(xì)胞的醫(yī)療產(chǎn)品均符合全球最高監(jiān)管標(biāo)準(zhǔn)。舒迪安公司的研發(fā)和生產(chǎn)基地位于布拉格，這一地理位置有利于我公司產(chǎn)品在整個(gè)歐洲范圍內(nèi)的快速流通

SOTIO is a biotechnology company developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. Our mission is to develop new medical therapies using our proprietary cell-based technologies to treat highly unmet medical conditions using our immunotherapy platform.

World renowned scientists are working at Sotio's research facilities in Prague using state-of-the art technologies to understand the role of dendritic cells in the therapeutic activation of the body's immune response.

Implementing autologous cellular immunotherapy approaches for the treatment of cancer and autoimmune diseases
Utilizing immunotherapy combined with other standard treatment modalities such as chemotherapy to improve clinical outcomes
Investigating the effect of long-term treatment with immunotherapy to enhance the immune system's response to a particular disease
Using a wide spectrum of tumor antigens to induce a complex immune response through activation of a patient's own dendritic cells.
Our clinical development programs are designed to use activated dendritic cell immunotherapy to expand treatment options targeting those diseases where few treatment alternatives exist.

Early clinical trials in advanced stage prostate cancer have shown promising preliminary results using our proprietary immunotherapy platform. We are planning on initiating confirmatory phase III worldwide clinical studies in 2012 with the aim of offering this therapy to those patients who have limited options.

SOTIO's therapies are produced in a state-of-the-art good manufacturing practices (GMP) cell therapy manufacturing facility that is among the largest in Europe. Our cell manufacturing facility meets the highest regulatory standards world-wide for the production of cellular based medicinal products. The facility's location in Prague expedites the transport of our products throughout Europe.